I feel there is still a decent amount of growth in this company. It’s Covid related work has created a good buzz around the company which will hopefully bring investment and expansion.
More importantly I think it could well be a company that gets brought out by one of the big players who would have the financial resources to take the work to the next level.
there is certainly a lot of emotion around novacyt, personally, as someone who requested this stock be added back in january, i do not believe their current contracts and sales warrant today’s valuation, and even if their contracts doubled again i don’t reach the current valuation. Additional concern is that governments will move away from PCR to more novel rapid testing solutions - novacyt have a rapid POC solution, but so do heaps of other companies. It’s worth remembering that while the market may think oh there are only a handful of other listed companies offering testing solutions, there are even more private companies also offering competing services. Just because you can’t invest in them doesn’t mean they don’t eat up market share. I sold at £7 and am staying out unless the price corrects a lot, but that seems unlikely in the short term given the numbers of uber fans.
Cheers James! This was a highly insightful comment.
Meanwhile the directors seems bullish. Do you have any thoughts on this development?
https://novacytinsider.com/director-purchases/
Ultimately, I think I’ll wait and monitor the situation for a few weeks before I decide.
Link from the app is broken.
This company is still making bank from all the covid testing that’s going on.
New C-19 variants, heading into winter
New European lockdowns
NCYT up like 50% in recent weeks, still way low compared to earlier in the year before contract failure
Do we think NCYT/Testing stocks are going to make a comeback over winter?
Private Eye article about Novayct 
£134.6m DHSC claim 
“However, planning is underway to prepare for any cases that we might see in the UK. This includes ensuring that clinicians are aware and able to recognise cases promptly, that rapid testing is available, and that protocols are developed for the safe clinical care of people who have the infection and the prevention of onward transmission.”
And…
Hopefully plenty testing, catch any cases early and no huge problems come of it.
new strain apparently in uk
Hotel and airline stocks plunged up to 6.4% as India confirmed three Human Metapneumovirus (HMPV) cases. The news revived COVID-era fears, triggering sharp declines in hospitality and aviation shares, with notable drops in The Indian Hotels Company and Interglobe Aviation.
What am I missing with this one? I know it’s old “covid” share but they’ve plenty going on aside.
Cash position at 31 December 2024 was £30.5m (30 June 2024: £32.9m), and the Group remains debt free.
Unaudited Group statutory revenue for FY 2024 is expected to be c. £19.6m (FY 2023*: £10.6m) representing a YoY growth of 85%
£35m market cap. No debt, cash of £30m. Growth from acquisition.
Unloved it seems.
